

DAFTAR PUSTAKA

1. Moda Arsana, *et al.* K. W. Panduan Pengelolaan Dislipidemia di Indonesia-2015 Penulis Penerbit PB. PERKENI. (2015).
2. Perk, J. *et al.* European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). *Eur. Heart J.* 33, 1635–1701 (2012).
3. Lu, L. *et al.* The Inflammatory Heart Diseases: Causes, Symptoms, and Treatments. *Cell Biochem. Biophys.* 72, 851–855 (2015).
4. Rivera-Mancía, S. *et al.* Activity of antioxidant enzymes and their association with lipid profile in Mexican people without cardiovascular disease: An analysis of interactions. *Int. J. Environ. Res. Public Health* 15, (2018).
5. Toth, P. P. *et al.* Management of Statin Intolerance in 2018: Still More Questions Than Answers. *Am. J. Cardiovasc. Drugs* 18, 157–173 (2018).
6. Abdoli, N., Azarmi, Y. & Eghbal, M. A. Protective effects of N-acetylcysteine against the statins cytotoxicity in freshly isolated rat hepatocytes. *Adv. Pharm. Bull.* 4, 249–254 (2014).
7. Mokhtari, V. *et al.* A Review on Various Uses of N-Acetyl Cysteine Citation: Mokhtari V, Afsharian P, Shahhoseini M, Kalantar SM, Moini A. A review on various uses of N-acetyl. *CELL JOURNAL(Yakhteh) Cell Journal(Yakhteh) Cell J* 19, 11–17 (2017).
8. Nagoor Meeran, M. F, *et al.* Preventive effects of N-acetyl cysteine on lipids, lipoproteins and myocardial infarct size in isoproterenol induced myocardial infarcted rats: An in vivo and in vitro study. *I. Nagoor Meeran, M. F., Stanely Mainzen Prince, P. Hidhayath Basha, R. Prev. Eff. N-acetyl cysteine lipids, lipoproteins Myocard. infarct size isoproterenol Induc. Myocard. infarcted rats An vivo Vittr. study. Eur. J* 677, 116–122 (2012).
9. Wei feing, *et al.* Exploration of dyslipidemia prevalence and its risk factors in a coastal city of china: A population-based cross-sectional study. *Int. J. Clin. Exp. Med.* 12, 2729–2737 (2019).
10. Alshamiri, M. *et al.* Expert opinion on the applicability of dyslipidemia guidelines in Asia and the middle east. *Int. J. Gen. Med.* 11, 313–322 (2018).

11. Wong, N. D. Epidemiological studies of CHD and the evolution of preventive cardiology. *Nat. Rev. Cardiol.* 11, 276–289 (2014).
12. Narain, J. P., Garg, R. & Fric, A. Non-communicable diseases in the South-East Asia Region: Burden, strategies and opportunities. *Natl. Med. J. India* 24, 280–287 (2011).
13. Mansbridge, J. RISKESDAS. *Ris. Kesehatan. DASR* 7, 803–809 (2013).
14. Kemenkes RI. Laporan Nasional Riset Kesehatan Dasar. *Kementeri. Kesehatan. RI* 1–582 (2018).
15. Indriani, S., Yasa, A. & Wasyanto, T. Effects of N-Acetylcystein on Hscrp Level in Acute Myocardial Infarction Patients Receiving Fibrinolytic Therapy. *Indones. J. Cardiol.* 39, 145–155 (2019).
16. Mada, S. B. *et al.* Hypolipidemic effect of N-acetylcysteine against dexamethasone-induced hyperlipidemia in rats. *Calabar J. Heal. Sci.* 3, 59–67 (2020).
17. Charron, M. J. *et al.* Antioxidant effects of n-acetylcysteine prevent programmed metabolic disease in mice. *Diabetes* 69, (2020).
18. Cui, Y. *et al.* N-acetylcysteine inhibits in vivo oxidation of native low-density lipoprotein. *Sci. Rep.* 5, 1–9 (2015).
19. Lee, K. S., Chun, S. Y., Kwon, Y. S., Kim, S. & Nam, K. S. Deep sea water improves hypercholesterolemia and hepatic lipid accumulation through the regulation of hepatic lipid metabolic gene expression. *Mol. Med. Rep.* 15, 2814–2822 (2017).
20. Mittal, M., *et al.* Reactive oxygen species in inflammation and tissue injury. *Antioxidants Redox Signal.* 20, 1126–1167 (2014).
21. Forrester, S. J, *et al.* Reactive oxygen species in metabolic and inflammatory signaling. *Circ. Res.* 122, 877–902 (2018).
22. G Morabito , P Kucan, M. S. Endocrine , Metabolic & Immune Disorders - Drug Targets. *J. food Microbiol.* 15, 1–2 (2015).
23. Peluso, I. *et al.* High Fat Meal Increase of IL-17 is Prevented by Ingestion of Fruit Juice Drink in Healthy Overweight Subjects. *Curr. Pharm. Des.* 18, 85–90 (2012).

24. Aldini, G. *et al.* N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. *Free Radic. Res.* 52, 751–762 (2018).
25. Rushworth, G. F. & Megson, I. L. Existing and potential therapeutic uses for N-acetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits. *Pharmacol. Ther.* 141, 150–159 (2014).
26. Bali, S. & Utaal, M. S. Serum lipids and lipoproteins: a brief review of the composition, transport and physiological functions. *Int. J. Sci. Reports* 5, 309 (2019).
27. Priya, T., Maurya, S. & Khan, K. H. Research Journal of Pharmaceutical , Biological and Chemical Sciences Cholesterol : Genetic , Clinical and Natural Implications. 4, 1344–1364 (2013).
28. Eckel, R. H. What is it about very low density lipoproteins (VLDL) and cardiovascular disease in patients with type 2 diabetes mellitus: Is it the triglycerides or the cholesterol? *Atherosclerosis* 237, 138–139 (2014).
29. Kesh, S. B., Sarkar, D. & Manna, K. High-fat diet-induced oxidative stress and its impact on metabolic syndrome: A review. *Asian J. Pharm. Clin. Res.* 9, 38–43 (2016).
30. Cortez, M, *et al.* A high-fat diet increases IL-1, IL-6, and TNF- α production by increasing NF- κ b and attenuating PPAR- γ expression in bone marrow mesenchymal stem cells. *Inflammation* 36, 379–386 (2013).
31. Balducci, Stefano, *et al.* Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low-grade inflammation and the development of obesity and diabetes. *Diabetes. Metab. Res. Rev.* 32, 13–23 (2014).
32. Popa, C., *et al.* The role of TNF- α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. *Journal of Lipid Research* 48, (2007).
33. Musco, F. & van Staden, M. Conclusion. *Adv. Glob. Chang. Res.* 39, 415–419 (2010).
34. Horiuchi, T., *et al.* Transmembrane TNF- α : Structure, function and interaction with anti-TNF agents. *Rheumatology* 49, 1215–1228 (2010).

35. Urschel, K. & Cicha, I. TNF- α in the cardiovascular system: From physiology to therapy. *Int. J. Interf. Cytokine Mediat. Res.* 7, 9–25 (2015).
36. Subedi, L. *et al.* Phytochemicals against TNF α -mediated neuroinflammatory diseases. *Int. J. Mol. Sci.* 21, (2020).
37. Li, G. *et al.* Serum levels of tumor necrosis factor alpha in patients with IgA nephropathy are closely associated with disease severity. *BMC Nephrol.* 19, 1–9 (2018).
38. Yin, J. *et al.* Changes and significance of inflammatory cytokines in a rat model of cervical spondylosis. *Exp. Ther. Med.* 15, 400–406 (2018).
39. de Andrade, K. Q. *et al.* Oxidative stress and inflammation in hepatic diseases: Therapeutic possibilities of N-acetylcysteine. *Int. J. Mol. Sci.* 16, 30269–30308 (2015).
40. Kerksick, C. & Willoughby, D. The Antioxidant Role of Glutathione and N-Acetyl-Cysteine Supplements and Exercise-Induced Oxidative Stress. *J. Int. Soc. Sports Nutr.* 2, (2005).
41. Tobwala, S. & Ercal, N. *N-acetylcysteine amide (NACA), a novel GSH prodrug: Its metabolism and implications in health. Glutathione: Biochemistry, Mechanisms of Action and Biotechnological Implications* (2013).
42. Li, H. *et al.* MiRNA-181a Regulates Adipogenesis by Targeting Tumor Necrosis Factor- α (TNF- α) in the Porcine Model. *PLoS One* 8, 1–11 (2013).
43. Šalamon, Š., *et al.*, I. Medical and dietary uses of n-acetylcysteine. *Antioxidants* 8, 1–16 (2019).
44. Korou, L. M. *et al.* Impact of N-acetylcysteine and sesame oil on lipid metabolism and hypothalamic-pituitary-adrenal axis homeostasis in middle-aged hypercholesterolemic mice. *Sci. Rep.* 4, 1–8 (2014).
45. Novelli, E. L. B. *et al.* N-acetylcysteine in high-sucrose diet-induced obesity: Energy expenditure and metabolic shifting for cardiac health. *Pharmacol. Res.* 59, 74–79 (2009).
46. Kaga, A. K., *et al.* Effect of N-Acetylcysteine on dyslipidemia and carbohydrate metabolism in STZ-induced diabetic rats. *Int. J. Vasc. Med.*

- 2018, (2018).
47. Wadwa, R. P., Urbina, E. M. & Daniels, S. R. Cardiovascular disease risk factors. *Epidemiol. Pediatr. Adolesc. Diabetes* 235–249 (2008). doi:10.3109/9781420047981-16
 48. Saggini, A. *et al.* Cholesterol, cytokines and diseases. *Int. J. Immunopathol. Pharmacol.* 24, 567–581 (2011).
 49. Piste, P. & Patil, V. Cholesterol and health. *Resonance* 11, 74–77 (2006).
 50. La Gerche, A. *et al.* Relationship between inflammatory cytokines and indices of cardiac dysfunction following intense endurance exercise. *PLoS One* 10, 1–15 (2015).
 51. Huang, W. Y. *et al.* Circulating interleukin-8 and tumor necrosis factor- α are associated with hot flashes in healthy postmenopausal women. *PLoS One* 12, 2–13 (2017).
 52. Choudhury, P., *et al.* Association of Serum TNF-Alpha with Thyroid Parameters: A Hospital Based Study. *Int. J. ...* 6, 30–32 (2019).
 53. Othman, N. A. *et al.* The effect of diode laser and topical steroid on serum level of TNF-alpha in oral lichen planus patients. *J. Clin. Exp. Dent.* 8, e566–e570 (2016).
 54. Glass, C. K. & Olefsky, J. M. Inflammation and lipid signaling in the etiology of insulin resistance. *Cell Metab.* 15, 635–645 (2012).
 55. Sit, M., Yilmaz, E. E., Tosun, M. & Aktas, G. Effects of N-acetyl cysteine on lipid levels and on leukocyte and platelet count in rats after splenectomy. *Niger. J. Clin. Pract.* 17, 343–345 (2014).
 56. Christianty, F. M., Suharjono, Susilo, I. & Khotib, J. Preventive Effects of Alpha-Lipoic Acid on Lipopolysaccharide-Induced Endothelial Dysfunction in Rats. *Pharm. Sci. Res.* 6, 124–130 (2019).
 57. Trisnadi. Pengaruh Ekstrak Biji (*Salvia Hispanica*) Terhadap Profil Lipid dan Kadar TNF α . Universitas Islam Sultan Agung Semarang. 2020.
 58. Purukan, J. A., *et al.* Perbandingan Profil Lipid dan Penentuan Indeks Aterogenik pada Tikus Putih Jantan yang Diberi Crude Fucoidan dari Rumput Laut Coklat (*Sargassum Polycystum*) yang Diinduksi Diet Tinggi

- Lemak (Comparison of Lipid Profile and Determination of Atherogenic. 17, 46–55 (2019).
59. Sadegh, M. & Palizvan, M. Transgenerational modification of hippocampus TNF- α and S100B levels in the offspring of rats chronically exposed to morphine during adolescence. (2017). doi:10.1080/00952990.2017.1348509
 60. Audina Mutia. *Pemeriksaan Profil Lipid pada Pasien Laboratorium Kesehatan Daerah Provinsi Sumatera Utara*. (2016).
 61. Ferencić, A., Šoša, I., Stemberga, V. & Cuculić, D. Obesity-related low-grade chronic inflammation: implementation of the dietary inflammatory index in clinical practice is the milestone? 54, 108–117 (2018).
 62. Nurhidajah, Astuti, R. & Nurrahman. Black rice potential in HDL and LDL profile in sprague dawley rat with high cholesterol diet. *IOP Conf. Ser. Earth Environ. Sci.* 292, (2019).
 63. Santos, H. O. & Macedo, R. C. O. Impact of intermittent fasting on the lipid profile: Assessment associated with diet and weight loss. *Clin. Nutr. ESPEN* 24, 14–21 (2018).

